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Abstract
In France, about 40% of women aged 25–65 years do not participate in regular screening and thus are at high risk (HR) of cervical cancer.
Human papillomavirus (HPV) vaginal self-sampling is a valuable alternative in this population. This study aimed to assess the prevalence of HR
and LR (low-risk) HPV infection in 3767 women aged >35 years from mid-socioeconomic backgrounds who carried out HPV vaginal self-
sampling at home. HPV vaginal self-sampling was better accepted than the Pap-test in women aged 35–69 years who were previously non-
responders to individual invitation. From the 933 self-collected swabs studied (24.7%), 62 were HPV-infected (6.6%), and 73 HPV types were
found. HPV 16 was the most frequently found (43.5%), followed by 53 (23.2%), 18 (12.3%), 66 (12.3%), 31 (6.8%), 33 (5.4%) and 58 (2.7%). Ten
women (16.2%) were infected by multiple HR-HPV types. Median HPV 16 load was 104.000 copies/106 cells and median HPV 18 load was 833
copies/106 cells. Six women (9.3%) harboured LR-HPV types. The 12-month follow-up of 43 HR-HPV positive women (69.3%) revealed CIN2–
3 lesions in three women (6.9%), all HPV 16 infected, and harbouring an HPV 16 load >5 log10 copies/10
6 cells. Women harbouring HR-HPV
types other than HPV 16/18 were older than women harbouring HPV 16/18 types (55 years vs. 46.9 years, p 0.0008). The high frequency of
HR-HPV types in women >50 years deserves further investigation to elucidate the mechanism involved (re-infection or reactivation).
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Introduction
High-risk oncogenic human papillomavirus (HR-HPV) infection
is the major risk factor for the development of cervical cancer
and cervical intraepithelial neoplasia (CIN) [1].
In France, 3000 new cases of cervical cancer are detected
each year, leading to 1000 deaths per year [2]. Cervical cancer
screening is performed on an individual basis and about 44% of
the target population is not screened [3]. Cytological screening
is often stopped at the age of 60 or 65 years, yet cancer
incidence and mortality tend to increase from the age of
65 years [4]. According to recent studies, HPV DNA testing,
in addition to cytology, could be useful for primary cervical
cancer screening [5,6]. Among women aged 35 years or older,
primary HPV screening with cytology triage displayed a higher
speciﬁcity than conventional Pap-smear screening [7]. In
addition, HPV 16 viral load correlates with the severity of
cervical lesions [8–10].
HPV vaginal self-sampling appears particularly useful for
women with infrequent access to gynaecological healthcare
[11–13] or refusing cytological screening because of cultural
barriers or reluctance to have vaginal speculum examination.
In addition, more than 50% of all cases of cervical cancer are
observed among women who do not respond to an invitation
to have a Pap-test [14]. Moreover, the quality of self-sampling
is usually satisfactory whatever the age. By contrast, in post-
menopausal women the transformation zone is scarcely visible
and the performances of cervical cytology are markedly
decreased [15]. Recently, a preliminary pilot study using
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vaginal self-sampling for HPV testing was undertaken in two
suburbs in the northern part of Marseille, where the socio-
economic level is low [13]. The rate of HPV infection was
23.3%, with 14.1% of HR-HPV types, including 25% of HPV-
type 16. In that study, the age of HR-HPV-infected, LR-HPV-
infected and multiple HPV-infected women was 42, 48 and
55 years, respectively.
The present study aimed to assess the prevalence of HR-
and LR-HPV infection as well as HPV 16 or 18 load in women
aged 35 years and older from two mid-socioeconomic cities
around Marseille: Vitrolles and Marignane. These two cities
have a relatively good healthcare system, but we tested
women aged 35–65 years who did not attend regular
cytological screenings for cervical cancer (referred to hereaf-
ter as non-attending). For this reason, self-collected vaginal
swabs were considered valuable tools for detecting HPV
infection, especially oncogenic HPV infection. Another objec-
tive was to evaluate the compliance with follow-up in this
target population.
Methods
Study population: the target population was composed of
women aged 25–69 years living in two cities around Marseille
(Vitrolles and Marignane) without a Pap-smear recorded in the
National Insurance Registry for more than 2 years. A total of
17 330 women were invited to have a Pap-smear by individual
mailing, free of charge in a local medical analysis laboratory.
The number of women participating in self-sampling HPV tests
was, however, limited by the ﬁnancial support for the study
(i.e. 4000 tests).Therefore, 9334 women aged 35–69 years
without a Pap-test for more than 2 years (national insurance
listing) who had not responded to a ﬁrst invitation to undergo
cytology were randomized into two groups: 4934 women
receiving a second invitation to have a Pap-test and 4400
women receiving a proposal to perform HPV self-sampling at
home.
The small unbalance between the two groups was due to
the limited ﬁnancial support for self-tests. After exclusion of
633 women for refusal or recent cytological screening, 3767
women remained in the HPV self-sampling arm. The ﬂowchart
of the study design is shown in Fig. 1.
Cervical cytology analysis
Among the 4934 women who received a second invitation to
have a Pap-test, 4314 women were eligible for Pap-test
(reasons for ineligibility were refusal, hysterectomy and
pregnancy). Cervical cells were obtained using a cervical brush
for conventional cytological slides.
Cytology was carried out at private cytology laboratories,
and cytological diagnosis was carried out according to The
French National Agency of Health consensus guidelines on the
quality control of cervical smear screening [16] and formulated
according to the 2001 Bethesda classiﬁcation [17].Those
carrying out cervical cytology analyses were blinded to the
result of HPV genotyping.
Vaginal self-sampling and virological analysis
Flocked swabs (Copan Diagnostics, Brescia, Italy) were used as
self-sampling devices. The women sampled their vaginal ﬂuid
using UTM tubes containing universal transport medium. The
collected material was returned via mail in a prepaid envelope
to the Department of Virology of the Timone Hospital
(Marseille, France) and was stored at 20°C until use. After
thawing, 250 lL of vaginal cell suspension was used for DNA
puriﬁcation using the QIAampDNA Mini Kit (QIAGEN,
Courtaboeuf, France) modiﬁed as follows: samples were
incubated at 56°C for 2 h in lysis solution containing protein-
ase K. The DNA was eluted in 100 lL of elution buffer and
stored at 20°C until use. HPV genotyping was assessed by
PCR (MY09/ MY11 primers), sequencing, phylogenetic analysis,
and cloning if necessary, as described [13]. Quantitations of
HPV 16 and 18 positive samples were performed using the
quantitative duplex real-time PCR method, as reported [8].
HPV viral load was expressed as the number of HPV copies
per million cells.
To follow-up abnormal tests, the virology and cytology
laboratories communicated their results to the management
centre ‘ARCADES’ in charge of sending them to the women
with recommendations and to their referent physicians. A
reminder regarding the management of abnormal results was
also sent to these practitioners (gynaecologycal examination
and colposcopy in the case of abnormal Pap-test and gynae-
cological examination and Pap-test if HPV-HR positive). The
collection of follow-up data for abnormal tests was also
monitored (mailing and telephone call) by the ARCADES
centre after 3, 6 and 12 months.
Ethical approval
Ethical approval was given by the ethical committee of ‘Sud
Mediterrane´e 2 and Marseille 2’ for all randomized studies on
HPV testing in the Bouches du Rhoˆne area performed by the
ARCADES association.
Statistical analysis
Statistical analysis was performed using the SPSS (version 12.0)
and EPI INFO 6 softwares. A Yates’s corrected chi-squared test
was used to detect differences between groups. A descriptive
analysis of the frequency and the distribution of the various
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HPV types and a comparison of median values using the
Kruskal–Wallis test were performed.
Results
Participation in the re-invitation to have a Pap-smear and to
carry out self-sampling in women aged 35–65 years
In the study group, the rate of attendance at the second Pap-
smear screening invitation was 7.3%, compared with 25.1%
who carried out self-sampling of vaginal ﬂuid at home
(p <0.001; OR = 4.64 (95% CI, 4.04–5.34). The rate of
participation in Pap-smear screening did not decrease with
age.
Prevalence of HR- and LR-HPV infection
Data from 946 women (946/3767; 25.1%) were recorded. To
avoid false negative results, the samples from 13 women (1.3%)
were excluded from the study because of paucicellularity.
Finally, samples from 933 women (933/3767; 24.7%) were
analysed.
Sixty-two samples from the 933 women were HR-HPV
positive (6.6%), with 27 samples (43.5%) positive for HPV 16
(17 single infections and ten co-infections), nine samples
(14.5%) positive for HPV 18 (six single infections and three
co-infections) and 29 samples (46.8%) positive for other HR-
HPV types (Table 1). As shown in Fig. 2(A), among the 73
HR-HPV strains, the HR-HPV types most frequently found
were HPV 16 (n = 27, 43.5%), 53 (n = 17, 23.2%), 18 (n = 9,
12.3%), 66 (n = 9, 12.3%), 31 (n = 5, 6.8%), 33 (n = 4, 5.4%)
and 58 (n = 2, 2.7%). Among the 62 HPV-infected women,
six harboured ten LR-HPV types, including HPV type 6
(n = 3, 4.8%), 11, 70, 81 (n = 2, 3.2% each) and 23 (n = 1,
1.6%) (Fig. 2B), that were constantly associated with HPV
16 ± 18 types. Median HPV 16 viral load (104.000 copies/106
cells) was higher than median HPV 18 viral load (833 copies/
106 cells) (p <0.001).
The mean age of HPV-infected women was 51 ± 9.4 years,
and the mean age of non-HPV-infected women was
52 years ± 8.5. Among the 62 HPV-infected women, 32 were
 50 years, including 13  60 years. No age-related differ-
ences were found between groups of HPV-uninfected,
HPV-infected, HPV 16 or 18, multiple HPV-infected and LR-
HPV-infected women (non-signiﬁcant for all p values). Among
the 29 women harbouring HR-HPV types other than HPV 16
and 18, 20 women were  50 years, compared with nine
women  50 years (p 0.015). Women harbouring HPV 16 and
18 were signiﬁcantly younger (mean age, 46.9 years) than
Screening programme invitation 
17 330 women of medium socio-economical 
level 
25–69 years 
Without Pap-test for ≥2 years 
Randomisation 
n = 9334 women 35–69 years
Re-invitation to Pap-test 
n = 4934 
Direct mailing 
Self-sampling arm 
n = 4400 
Eligible n = 4314 
Age strata 
35–44 = 2047 
45–54 = 955 
55–64 = 1115 
65–69 = 197 
Self-HPV tests mailed n = 3767 
Age strata 
35–44 = 806 
45–54 = 1714 
55–64 = 895 
65–69 = 352
Exclusion of women aged 
25–35 years (Pap-test before 
randomisation, refusal, 
hysterectomy)
FIG. 1. Flowchart of the study design
TABLE 1. Main virological characteristics of 62 HPV-infected
women
HPV status N (%)
HR-HPV-infected women 62 (6.6)
Number of HPV 16
mono-infected women
17
Number of HPV 18
mono-infected women
6
Number of infected women with
HR-HPV types other than
HPV 16 or 18 (n)
29
HPV53 (14);HPV66 (8); HPV31
(5); HPV33 (1)
HPV58 (1)
Number of HPV16 + 18 dually
infected women
2
Number of HPV16 + 18 + other
HR-HPV-infected women
1
Number of HPV16 + other HR
HPV-infected women (n)
7
HPV16 + 33 (2); HPV16 + 53 + 61 (1)
HPV16 + 53(2); HPV16 + 66 (1)
HPV16 + 58 (1)
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women harbouring HR-HPV types (mean age, 55.1 years)
(p 0.0008). No relationship was observed between HPV 16 or
18 viral load and age.
Follow-up
After discovery of 62 women with positive DNA tests, at the
end of follow-up (i.e. 12 months after stopping the study), 43
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FIG. 2. (A) HPV-HR type distribution among 62 HPV-positive samples. (B). HPV-LR type distribution among 62 HPV-positive samples.
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of these 62 women were referred to their physician (i.e. a
follow-up rate of 67.7%) and were referred for cytology tests,
whereas 14 women had colposcopy and 13 women had biopsy
with the following data: three had CIN2+ (one CIN2, two
CIN3), four had CIN1, and 36 had normal cytology ﬁndings
(Table 2). Of note, all three CIN2+ lesions were related to
HPV 16 infection and revealed an HPV 16 viral load >5 log10/
106 cells in two CIN2+ cases and >6 log10/10
6 cells in one
CIN3 case.
Among the 4314 women eligible for the second invitation to
have a Pap-test, 315 women actually had a Pap-test, four
women had colposcopy and three women had a biopsy.
In the follow-up of women who responded to the second
invitation to have Pap smears, two high-grade lesions were
detected (both CIN3) among 17 abnormal cytological results.
Discussion
Since 2008, we have undertaken three campaigns including a
re-invitation to undergo a Pap-test or HPV self-sampling. Two
of these campaigns targeted low-income populations of the
northern part of Marseille in 2008 [13] and speciﬁcally the
poorest women living in the district of the Bouches du Rhoˆne
in 2010, who were recipients of universal health insurance
(UHI) with free access to care. The present study targeted
medium socio-economic level populations. If we consider the
three campaigns as a whole, in all, 31 945 women were eligible
for a second invitation to have a Pap-test, and 17 956 women
received an invitation to carry out HPV self-sampling. This
large sample size makes our research unique in France,
because we were the ﬁrst French team to undertake screening
campaigns combining re-invitation to have Pap-smears and
HPV-self sampling. Overall, in the three campaigns, the
participation rates were 4.9% for the second invitation to
have a Pap-test and 14.9% for the HPV test, respectively. This
represents a three-fold increase in the participation rate for
use of the HPV self-sampling device, which conﬁrms the good
acceptability of self-sampling in non-attendees, in agreement
with previous studies [11,18–20]. The highest participation
rates in self-sampling were observed in the present study
(25.1% vs. 2.3% in the pilot study, vs. 18.3% in the UHI study).
In the present study the targeted women had a medium
socio-economic level, improved access to and use of the
healthcare system, and a satisfactory public health setting. Of
note, a dramatic increase in the participation rate was noted in
‘lower’ social groups of women from the ﬁrst the pilot
campaign in 2008 to the last UHI trial in 2010. The higher
participation rate in self-sampling of the women from Vitrolles-
Marignane and the UHI trials (25.1% and 18.3%) was optimized
by the do-it-yourself at-home opportunity given by the device.
In contrast, the low-income women from the northern part of
Marseille had to go to a medical analysis laboratory to perform
the self-sampling [13]. Therefore efforts are ongoing to extend
these screening campaigns targeting women of low socioeco-
nomic position. Indeed a meta-analysis of social inequality in
cervical cancer showed an odds-ratio of 1.97 (95% CI, 1.80–
2.15) for cervical cancer among women of low socioeconomic
position compared with women of high socioeconomic
position [21].
The overall frequency of HPV infection, including mostly
HR-HPV types, was 6.6%, a frequency close to that found by
Sanner et al. [22] in Swedish women aged 55–60 years, and by
Go¨k et al. [18] in the Netherlands. It was lower than the rates
of 14% previously found in under-privileged women of
Marseille [13], or more recently in a large study in Mexico
[23], and much lower than the rates found by Stenvall et al.
[24] in Swedish women aged 35–50 years, and by Rossi et al.
[19] in Italian women aged 35–64 years (26% and 21.8%,
respectively).
Most HPV self-sampling studies are based upon the Hybrid
capture II assay, which does not discriminate the different HR-
HPV types. In the present study, the use of PGMY 09/11 PCR
or HPV 16/18 real-time PCR allowed HR- and LR-HPV types
to be accurately genotyped. Thus, HR-HPV types other than
HPV 16 (including HPV 53, 31, 33, 66) were more frequently
found than the HPV 16 type (37/62, 59.6% vs. 27/62, 43.5%),
which is in line with other studies [13,25]. In a recent study,
the most prevalent HR-HPV types, 16 and 31, conferred the
highest risk of HSIL in women with abnormal cytology results
and referred to colposcopy [26]. Yet, in a previous French
study, HPV 16, 18, 66, 31, 33 and 58 were the most prevalent
HR-HPV types in women with HG CIN2+ lesions [27].
Regarding prevention policy, although a vaccine against HPV
16 and 18 could theoretically prevent about 50% of HSILs,
genotypes not covered by the vaccine were frequent in our
target population. However, note that the three CIN2+ lesions
TABLE 2. Follow-up of 43 HPV-positive women at 12
months
HPV-positive women, n 62
Women referred to colposcopy, n (%) 14 (22.6)
Women who had biopsies, n (%) 13 (30.2)
Women who had surgery, n (%) 5 (11.6)
Histology results, n (%)
CIN1 4* (9.3)
CIN2 1** (2.3)
CIN3 2*** (4.6)
Normal cervix 36 (83.7)
*Including one HPV16+HR-HPV, three HR-HPV types.
**Including one HPV16+.
***Including two HPV16+.
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revealed by self-sampling HPV typing in this study were related
to HPV 16, which conﬁrms, as reported by others [27, 28],
that HPV 16 is the most common type detected among
women with abnormal cytology. Moreover, in these three
CIN2+ lesions, HPV 16 viral load was elevated (at 104.000
copies/106 cells, 104.000 copies/106 cells and 1.000.000 copies/
106 cells). Interestingly, these three HPV 16 load values are
close to the cut-off of 3.0 9 106 copies per million cells
predictive of CIN2+ lesions (91% speciﬁcity, 58.2% sensitivity),
as pointed out recently [29].
A previous study had also deﬁned an HPV 16 load cut-off
value of 21 9 106 copies per million cells to be predictive of
CIN2+ lesions [8]. Altogether, these data suggest that a high
HPV 16 viral load plays a role in oncogenic HPV persistence
and progression to cervical lesions.
In this study, about 16% of women harbouring HR-HPV types
were infected with multiple HPV types. Co-infection in women
with multiple HPV types is a common ﬁnding of many molecular
studies, and according to someauthors, this could increase the risk
ofHG-lesions and invasive cancers relative towomenharbouring a
single HPV type [30], although this is still debated [31].
Regarding the relationship between the age and the
presence of HPV 16/18 and presence of HR-HPV types other
than HPV 16, the present study revealed that HPV 16/18-
infected women were younger (47.7 years) than HR-HPV-
infected women (54.3 years).One of the major outcomes of
this study was the high frequency of HR-HPV types other than
HPV 16 in women >50 years. This ﬁnding is consistent with a
second peak reported by others in HPV prevalence [26,32]
and the hypothesis of a potential re-infection of women
>50 years with HPV, or reactivation of latent infection in the
post-menopausal period due to decreasing speciﬁc immunity.
To draw ﬁnal conclusions about the role of HR-HPV types
other than HPV 16 in the development of CIN2+, further
studies will have to follow-up a higher percentage of women
participating in self-sampling and harbouring HR-HPV types.
The main limitation of this study was that not all women
with HR-HPV positive tests performed cytology or histology
testing so that the three HG lesions detected further were
probably underestimated. Interestingly, the strength of the
recent large Mexican study was the systematic implementation
of reference standard mobile colposcopy concomitant with
positive HPV tests [23].
The present results, which revealed three CIN2+ cervical
lesions (6.9%) among the 43 HR-HPV-infected women with a
1-year follow-up, should be compared with the results of the
recent UHI trial conducted in free healthcare centres for low-
income women in the Marseille area in 2010. In that study,
1604 self-collected cervicovaginal samples were obtained,
including 283 HR-HPV-positive samples (17.5%). At 1 year of
follow-up, 117 women (41%) were re-evaluated by
cytology ± colposcopy and biopsy, which revealed a higher
frequency of CIN2+ lesions, including two cancers in the more
precarious low-income women (nine CIN1, nine CIN2, one
in situ cancer and one invasive cancer (9.4%) (Sancho-Garnier H,
Tamalet C, Halfort P, Leandri FX, Heid P, Le Retraite L, Piana L,
unpublished data). Another limitation was the lack of second
HPV testing 12 months later in most HPV-positive women to
identify whether HR-HPV types detected at ﬁrst were transient
or persistent; in this latter case, a referral to immediate
colposcopy should be the rule.
Conclusion
This study conﬁrms that self-sampling is an attractive alterna-
tive strategy to Pap-smear screening to increase the partici-
pation of unscreened women. The quality of self-sampling is
highly satisfactory and allows detection of more lesions than by
Pap-smear screening, especially in elderly women who are not
adequately screened. However, compliance with follow-up
remains to be improved to validate the increased coverage by
a marked detection of CIN2+ lesions.
This study also points out the need to regularly survey the
distribution of HPV types in target populations to adapt
vaccines for protection against the prevailing HPV types.
Indeed, HR-HPV types other than HPV 16 were more
widespread than expected (59.6% vs. 43.5%), although the
three HG lesions observed were only related to HPV 16
accompanied by an elevated HPV 16 viral load.
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